THERIVA BIOLOGICS INC

Theriva Biologics (TOVX) drops 5% amid biotech market volatility; investors weigh low cap, thin volume, and its adenovirus platform outlook.

Theriva Biologics (TOVX) dips 4.8% as its adenovirus‑based anti‑tumor platform faces market volatility, underscoring the need to watch clinical milestones and biotech sector trends.

Explore Theriva Biologics’ latest trading data and upcoming shareholder vote on Nov. 18, 2026, plus a snapshot of key market movers and company overview.

Theriva Biologics slides 5%, yet its adenovirus platform offers a unique anti‑tumor strategy amid volatile biotech markets—find out why investors are watching closely.